Key result
Inoculation with a recombinant herpes simplex virus lacking the protease gene was avirulent and protected mice from subsequent lethal challenge with wild-type virus in a dose-dependent manner.
Provides preclinical support for protease-deficient HSV as vaccine candidate; leaves open safety and efficacy in humans.
Null mutants and attenuated mutants of herpes simplex virus (HSV) have been shown to induce immunity against challenge from wild-type virus. Null viruses with a defect in late gene products would be expected to express more viral genes than viruses with defects in essential early gene products and thus induce a better immune response. Herpesviruses encode a late gene product (serine protease) that is autocatalytic and cleaves the capsid assembly protein during viral replication. To determine whether a virus with a mutation in this gene could induce immunity, we constructed a recombinant virus containing the gusA reporter gene in the protease domain of the HSV type 1 UL26 open reading frame (ORF). Consistent with previous results (M. Gao, L. Matusick-Kumar, W. Hurlburt, S. F. DiTusa, W. W. Newcomb, J. C. Brown, P. J. McCann, I. Deckman, and R. J. Colonno, J. Virol. 68:3702-3712, 1994), recombinant virus could be isolated only from helper cell lines expressing the product of the UL26 ORF. Mice inoculated with the recombinant virus were unaffected by doses of virus that were lethal to mice infected with wild-type virus. Mice which were previously inoculated with the recombinant virus were also protected by a subsequent challenge with wild-type virus in a dose-dependent manner. These results indicate that recombinant viruses lacking the protease gene are avirulent but render protection from subsequent challenge.
No takes yet. Share an insight, caveat, or question.
Hippenmeyer et al. (1997) studied Lethal herpesvirus infection. Recombinant herpes simplex virus lacking the protease gene vs. Wild-type virus was evaluated on Protection from subsequent challenge with wild-type virus. Inoculation with a recombinant herpes simplex virus lacking the protease gene was avirulent and protected mice from subsequent lethal challenge with wild-type virus in a dose-dependent manner.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: